

- Racial/ethnic disparities in health care (*Cont.*):
 recommendations to address, 16e-5-6
 root causes for, 16e-2-5
- Racism, 16e-4
- Rad, 103e-4, 263e-1
- Radial artery, for PCI access, 296e-1
- Radial neuropathy, 463e-4, 463e-5f, 2691
- Radiation, 263e-1. *See also* Ionizing radiation
- Radiation dose, 103e-4
- Radiation enteritis, 1940t
- Radiation esophagitis, 1910
- Radiation sensitizers, 103e-4
- Radiation syndrome, acute, 263e-2-4, 263e-4f
- Radiation terrorism, **263e-1**
 acute radiation syndrome, 263e-2-4, 263e-4f
 follow-up of exposed patient, 263e-7
 hospital management of, 263e-5-6, 263e-5f
 initial management of, 263e-4-5, 263e-4f, 263e-5f
 medical assay of radiation-exposed patient, 263e-7
 nuclear weapons, 263e-2
 radiologic dispersal events, 263e-2
 radionuclide properties and treatment, 263e-3t
 types of exposure, 263e-1-2
- Radiation therapy, **103e-4**
 for acromegaly, 2271
 adverse effects of, 103e-4
 bowel complications, 270, 583
 breast cancer, 103e-4, 524
 cardiovascular, 621, 1567, 1575
 cataract, 204
 cobalamin malabsorption, 646
 dysphagia, 256
 gastrointestinal, 1957
 head and neck, 505
 hepatic, 622
 in HIV infection, 1270
 hyperbaric oxygen therapy for, 477e-3, 477e-4t
 hypopituitarism, 2256, 2263-2264
 late, 620t, 621-623
 lymphedema, 1654
 myelofibrosis, 672
 nephropathy, 1864
 neurologic, 606-607, 622
 ocular, 623
 oral, 623
 pericarditis, 621, 1575, 1788
 pituitary, 2324t
 plexopathy, 2694
 pneumonitis, 489
 proctopathy, 346e-1v
 pulmonary, 621, 1797
 pulmonary eosinophilia, 1687
 soft tissue sarcoma, 119e-1
 testicular dysfunction, 2365
 thyroid cancer, 2304
 vascular, 103e-4
 for anal cancer, 544
 biologic effects of, 103e-4
 for bladder cancer, 576
 for bone pain, 61
 brachytherapy. *See* Brachytherapy
 for brain metastases, 605
 for breast cancer, 527-528
 for cholangiocarcinoma, 553
 for colorectal cancer, 543
 cranial, prophylactic in lung cancer, 522
 curative, 103e-4
 dosage of, 103e-4
 for ductal carcinoma in situ, 531
 for epidural metastases, 606
 for esophageal cancer, 533
 external beam. *See* External beam radiation therapy
 for gastric cancer, 535
 for head and neck cancer, 505
 for hepatocellular carcinoma, 551
 for Hodgkin's lymphoma, 709
 hyperbaric oxygen therapy for enhancement of, 477e-4t
 for lung cancer, 517, 518-519, 522
- modalities of, 103e-4
 physical properties of, 103e-4
 for pituitary tumors, 2263
 in pregnancy, 124e-1-2, 124e-1t
 for primary central nervous system lymphoma, 602
 for prostate cancer, 583
 quantitation of, 103e-4
 second malignancy and, 103e-4, 623, 709, 2264
 selective internal, 574
 for skin cancer, 501-502
 for soft tissue sarcoma, 119e-2
 systemic, 103e-22-23
 for testicular cancer, 590
- Radiculopathy, 111, 2692, 2692t
- Radiocontrast media. *See* Contrast agents
- Radiofrequency ablation
 for cardiac arrhythmias, 103e-6, 103e-6f
 characteristics of, 103e-5
 for chronic venous disease, 1652
 for hepatocellular carcinoma, 549
 for metastatic lesions, 103e-5
 for NETs, 574
- Radiofrequency denervation, 120, 1625
- Radiofrequency thermal rhizotomy, 2646
- Radioiodine therapy
 for Graves' disease, 2296-2297
 for hyperfunctioning solitary thyroid nodule, 2303
 for hyperthyroidism, 48
 for nontoxic multinodular goiter, 2302
 safety precautions for, 2297
 for thyroid cancer, 103e-22, 2306-2307
 for toxic multinodular goiter, 2302
- Radioiodine uptake, in thyroid evaluation, 2288
- Radionuclide contamination, 263e-6-7, 263e-6t
- Radionuclide scans/scintigraphy
 for colonic transit measurement, 273
 in gallbladder disease, 2078-2079, 2079t
 in gastrointestinal bleeding, 279
 in musculoskeletal disease evaluation, 2224, 2224t
 in NETs, 572, 572f
- Radium-233 chloride (alphanadin), 119e-4, 586, 587
- Radium exposure, 263e-3t
- Radon exposure, 506, 1693
- Raf kinase inhibitors, 102e-4f, 102e-17
- Ragged red fibers, 462e-15
- Rai staging system, for lymphoid malignancies, 700t
- Rales, 1504, 1662
- Raloxifene
 for breast cancer prevention, 478, 531
 for gynecomastia, 2367
 for osteoporosis prevention/management, 2383, 2499
- Raltegravir
 action of, 1281
 adverse effects of, 1275t
 for HIV infection, 214e-9, 1275t, 1281
 resistance to, 1280f, 1281
 structure of, 1276f
- Ramipril, 1624t
- Ramsay Hunt syndrome, 149, 237, 1185, 2648
- Ramucirumab, 535
- Randall's plaque, 1866
- RAND Health Insurance Experiment, 15e-2
- Random Forests analysis/machine learning, 86e-1t, 86e-4
- Range of motion, 2219t, 2220
- Ranibizumab, 205
- Ranitidine
 for carcinoid syndrome, 566
 for gastrinoma, 2337
 for GERD, 263
 for peptic ulcer disease, 1920, 1920t
- Ranitidine bismuth, 1922, 1922t
- RANK (receptor activator of NFκB)
 in bone metastasis, 102e-10-11
 in bone remodeling, 2490, 2492f
 in osteoclast and osteoblast differentiation, 426e-1f
 in Paget's disease of bone, 426e-1
 in rheumatoid arthritis, 2142f
- RANKL (RANK ligand), 102e-10
 in bone remodeling, 2455, 2490, 2492f
 in rheumatoid arthritis, 2142f, 2143
- Ranolazine, 1590
- RANTES, 372e-12t
- Rapamycin
 action of, 102e-4f, 465e-1
 for insulinoma, 569
 for Kaposi's sarcoma, 925
 for lifespan enhancement, 85, 94e-7
 for neurodegenerative diseases, 444e-9
 structure of, 94e-6f
- Rapeseed oil, 2218t
- Rapid acetylators, 40
- Rapid cycling, in bipolar disorder, 2717
- Rapid detection tests
 for group A streptococcal infections, 232
 for parasites, 245e-3
- Rapid reagent (RPR) test, 1137, 1137f
- RARA gene, 679
- Rarefaction, 86e-1t
- RAS (reticular activating system), 1771
- Rasagiline, 2615, 2616t
- Rasburicase
 adverse effects of, 1795
 genetic variations in response to, 39t, 40
 for tumor lysis syndrome treatment/prophylaxis, 431e-5, 1795
 for uric acid nephropathy, 681-682
- RAS gene mutations
 cancers associated with, 101e-2
 in hypercalcemia of malignancy, 609
 in juvenile myelomonocytic leukemia, 135e-6
 in melanoma, 496
 in thyroid cancer, 2304, 2305t
- Rash. *See also* Skin disorders/lesions; *specific diseases*
 centrally distributed maculopapular eruptions, 127, 128-130t, 134
 confluent desquamative erythemas, 130-131t, 134
 drug-induced, 25e-2f, 103e-26, 127, 380-381, 381f. *See also* Drug-induced illness, cutaneous
 with fever, **25e-1**, **127**, 128-134t, 369-370, 998
 in glucagonoma, 569
 morbilliform, 340t, 362, 362t
 nodular eruptions, 132-133t, 135
 peripheral eruptions, 130t, 134
 petechial, 999t, 1155, 1156f
 purpuric eruptions, 133t, 135, 999t
 pustular eruptions, 131-132t, 134-135
 scarlatiniform, 362-363, 362t
 ulcers and eschars, 133-134t, 135
 urticaria-like eruptions, 132t, 135
 vesiculobullous eruptions, 131-132t, 134-135
- Rasmussen's aneurysm, 245, 1108
- Rasmussen's encephalitis, 372e-24t
- Raspberry tongue, 241t
- Ras protooncogene, 102e-4f
- Rat-bite fever (Haverhill fever), 130t, 167e-1-2
- Rat-bite fever (sodoku), 129t, 167e-1-2
- Rat bite-wound, 167e-1-2
- Rat flea, 2750
- Rathke's cysts, 2264
- Rationing, 12e-3
- Rat lungworm. *See* *Angiostrongylus* spp. infections
- Rattlesnake bite, 2734, 2734f, 2736t, 2738. *See also* Snakebites
- Ravn virus disease, 1323, 1325f, 1326f
- R_{aw}. *See* Airway resistance (R_{aw})
- Raxibacumab, 261e-3
- Raynaud's phenomenon, **1647**
 chilblain in, 478e-4
 clinical features of, 1647-1649, 1648f
 cyanosis in, 249
 drug-induced, 590, 623, 1649
 in inflammatory myopathies, 2196
 localized hypoxia in, 248
 pathophysiology of, 372e-24t, 1648